Page 84 - Read Online

Page 8 of 13 Zeng et al. Cancer Drug Resist 2024;7:31 https://dx.doi.org/10.20517/cdr.2024.57

Table 2. circRNAs involvement in chemotherapy resistance of HNSCC
circRNA Tumor Expression Functions Targets Ref.
circCRIM1 NPC Upregulation Promote metastasis of NPC and resistance to docetaxel chemotherapy miR-422a [87]
circ-0008450 Upregulation Promotes NPC cisplatin resistance miR-338-3p [88]
circIPO7 Upregulation Promotes NPC cells to resist DNA damage triggered by cisplatin YBX1 [89]
circ-0067717 Upregulation Promote taxol resistance in NPC TRIM41; p53 [90]
circPARD3 Upregulation Promote the dryness and cisplatin resistance of NPC miR-579-3p [91]
circ-0028007 Upregulation Decreased sensitivity of NPC to paclitaxel/cisplatin \ [92]
circNRIP1 Upregulation Promote NPC drug resistance miR-515-5p [93]
circSETD3 Upregulation Promotes NPC cisplatin resistance miR-147a [34]
circPGM1 LSCC \ Promote cisplatin resistance in LSCC cells miR-376a [94]
circPARD3 Upregulation Promote the proliferation, migration, invasion and chemotherapy resistance of LSCC miR-145-5p [68]
circ-0004507 Upregulation Reduce the sensitivity of LSCC to cisplatin chemotherapy miR-873 [95]
circ-0005033 Upregulation Promote proliferation, invasion, migration and cisplatin resistance of LSCC miR-107 [70]
circ-ILF2 OSCC Upregulation Promote OSCC of cisplatin resistance cell carcinoma miR-1252 [96]
circAP1M2 Upregulation Promotes autophagy associated cisplatin resistance in OSCC miR-1249-3p [97]
circ-0109291 Upregulation Promote the proliferation and cisplatin resistance of intracavitary squamous cell miR-188-3p [98]
cells
circANKS1B Upregulation Promote the growth and drug resistance of intracavitary squamous cell carcinoma TGF-β1 [99]
circPKD2 Upregulation Promoting cisplatin sensitivity in OSCC miR-646 [49]

circRNAs: Circular RNAs; HNSCC: head and neck squamous cell carcinoma; NPC: nasopharyngeal carcinoma; LSCC: laryngeal squamous cell
carcinoma; OSCC: oral squamous cell carcinoma.

circRNAs and chemoresistance in oralsquamous cell carcinoma
Some circRNAs show significant differential expression between chemotherapy-resistant OSCC patients
and corresponding normal tissues. Wu et al. discovered that circILF2 is overexpressed in cisplatin-resistant
OSCC cells . As a miRNA sponge for miR-1252, circ-ILF2 inhibits miR-1252 expression. miR-1252
[96]
regulates the expression of Krüppel-like factor 8 (KLF8), which functions on proliferation, drug resistance,
and inflammation of OSCC, thereby promoting cisplatin resistance . The researchers identified
[96]
circAP1M2 (hsa-circ-0049282) as a miR-1249-3p sponge, inhibiting autophagy-related protein 9A (9A)
expression. circAP1M2 activates autophagy associated with ATG9A, thereby promoting cisplatin resistance
[97]
in OSCC . circ-0109291 is also overexpressed in cisplatin-resistant OSCC and promotes proliferation and
cisplatin resistance of OSCC cells through the miR-188-3p/ABCB1 axis . The circRNA circANKS1B (circ-
[98]
0007294), originating from exons 5 to 8 of the ANKS1B gene, is positively associated with the expression of
transforming growth factor-β1 (TGF-β1) in OSCC tissues. circANKS1B facilitates the growth and resistance
of OSCC by stimulating the TGF-β signaling pathway in oral cancer cells . circPKD2 is significantly
[99]
upregulated in cisplatin-treated OSCC and acts as a miR-646 sponge in OSCC cells. By inhibiting miR-646,
circPKD2 promotes the expression of autophagy-related protein 13 (ATG13), leading to the accumulation
[49]
of autophagic vesicles in cisplatin-treated OSCC cells and enhancing sensitivity to cisplatin [Table 2].
In conclusion, circRNAs have emerged as promising biomarkers for various cancers, including NPC,
OSCC, and LSCC. Their dysregulation affects the development and progression of these malignancies. By
further investigating the functional roles and underlying mechanisms of circRNAs in these cancers, we can
potentially discover new diagnostic and therapeutic targets. Therefore, circRNAs have significant potential
for enhancing the management and prognosis of patients with NPC, OSCC, and LSCC. Further research in
this area is necessary to fully comprehend circRNAs’ clinical implications and therapeutic uses in these
specific cancer types.